LLY · Stock research

Eli Lilly’s Mounjaro Turns $900 Million into a Side Hustle

Eli Lilly’s blockbuster drugs Mounjaro and Zepbound continue to dominate the obesity and diabetes markets, driving a 39% revenue surge in Q3 2026. But it’s the $900 million in rebate adjustments and milestone payments that stole the show, proving that even pha

Metalgo5 Research Desk · · 625 words
Metalgo5 · technical read · 1hNeutral

Data timestamp: Nov 7, 2026, 9:49 AM UTC · 4.2h

Price$1357.00
Trenddowntrend
MA 50 / 2001394.11 / 1351.79
RSI59.47
MACD46.37 / 48.59
Volumehigh · 1.53×

Metalgo5's 1h strategy signal is HOLD, score -12, 31.8% confidence, the trend is downtrend, price is below the 50-period average, the 50-period average is above the 200-period average, MACD is below its signal. The resulting Metalgo5 direction is Neutral. The screener also marks some options, tape or order-book inputs as stale, which lowers signal confidence.

Open LLY in Metalgo5 →
f  Share this article on Facebook
Open interactive chart ↗

In a quarter where Eli Lilly (LLY) once again outperformed expectations, the company’s revenue soared to $24.4 billion, a 39% increase year-over-year. While Mounjaro and Zepbound remained the stars of the show, it was the $900 million in favorable adjustments and milestone payments that added an unexpected twist to the narrative. This financial finesse allowed Lilly to raise its full-year revenue guidance by $5.5 billion, now targeting $91 billion to $92 billion. But behind the headline numbers, there’s more to unpack about how Lilly is navigating the competitive landscape of obesity and diabetes treatments.

The $900 Million Question

Eli Lilly’s Q3 earnings report might as well have been subtitled 'The $900 Million Side Hustle.' While Mounjaro and Zepbound drove the bulk of revenue growth, the company also benefited from $900 million in favorable adjustments to rebate and discount estimates, along with $410 million in Jardiance milestone payments [1]. These windfalls weren’t just a lucky break—they were a testament to Lilly’s ability to optimize its financial operations while delivering groundbreaking treatments.

But let’s not get carried away. These adjustments aren’t recurring revenue. The Jardiance milestones, for example, are a one-time boost. What’s more, acquired IPR&D charges weighed down earnings per share (EPS), with $4.57 per share in charges offsetting the gains. Still, Lilly managed to raise its full-year EPS guidance to a range of $35.00 to $36.00, a testament to its robust underlying performance [2].

Mounjaro and Zepbound: The Dynamic Duo

Mounjaro and Zepbound continue to be Lilly’s golden geese. Mounjaro, which saw a 65% year-over-year revenue increase to $10.7 billion, is now a staple in the treatment of type 2 diabetes and cardiovascular risk reduction [3]. Zepbound, Lilly’s obesity drug, isn’t far behind, with U.S. revenue jumping 48% to $5.3 billion. Together, these drugs accounted for nearly two-thirds of Lilly’s Q3 revenue.

But the road ahead isn’t all smooth sailing. Pricing pressures, particularly outside the U.S., have started to weigh on realized prices. Mounjaro’s inclusion on China’s National Reimbursement Drug List (NRDL) has driven volume growth but at lower prices. Still, Lilly’s ability to offset these pressures with higher-margin sales and strategic adjustments speaks to its resilience in a competitive market.

Pipeline Progress and Acquisitions

Lilly’s pipeline is brimming with potential. The company announced positive Phase 3 results for retatrutide, a head-to-head competitor to Novo Nordisk’s Ozempic, and Phase 2 results for EloraTZP in obesity and type 2 diabetes [4]. These developments position Lilly to maintain its dominance in the GLP-1 market, which continues to see insatiable demand.

On the acquisition front, Lilly closed deals with AtaiBeckley and Merida Biosciences, advancing its presence in mental health and autoimmune treatments. While these acquisitions came with hefty IPR&D charges, they underscore Lilly’s commitment to diversifying its portfolio and driving long-term growth.

What’s Next for Lilly?

With its updated guidance and strong pipeline, Lilly appears well-positioned for continued success. However, investors should keep an eye on pricing pressures, particularly in international markets, and the company’s ability to integrate its recent acquisitions. The GLP-1 market remains fiercely competitive, and Lilly’s ability to innovate and optimize will be critical to maintaining its edge.

In the meantime, Lilly’s Q3 performance is a reminder that even in a challenging environment, there’s always room for a $900 million side hustle. Whether it’s rebate adjustments or milestone payments, Lilly knows how to turn a corner when it needs to.

Sources

  1. Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio | Eli Lilly and Company
  2. Quarterly Results | Eli Lilly and Company
  3. Investors | Eli Lilly and Company
  4. SEC Filings | Eli Lilly and Company
  5. Form 10-Q for ELI Lilly Co filed 10/29/2026
  6. Annual Reports | Eli Lilly and Company
  7. Lilly reports third-quarter 2026 financial results, raises full-year ...
  8. Watch Eli Lilly Shares Surge on Raised Sales Forecast - Bloomberg

For information and research only. This article is not investment advice. Market data may be delayed.